Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in late-stage clinical development.

Yu, Wayne; Ramprasad, Mysore P; Pal, Manoj; Chen, Chris; Paruchuri, Shashi; Skidmore, Lillian; Knudsen, Nick; Allen, Molly; Buechler, Ying

Yu, Wayne; Ramprasad, Mysore P; Pal, Manoj; Chen, Chris; Paruchuri, Shashi; Skidmore, Lillian; Knudsen, Nick; Allen, Molly; Buechler, Ying.

Afiliação

Yu W; Ambrx Incorporated, La Jolla, CA, United States of America.
Ramprasad MP; Ambrx Incorporated, La Jolla, CA, United States of America.
Pal M; Ambrx Incorporated, La Jolla, CA, United States of America.
Chen C; Ambrx Incorporated, La Jolla, CA, United States of America.
Paruchuri S; Ambrx Incorporated, La Jolla, CA, United States of America.
Skidmore L; Ambrx Incorporated, La Jolla, CA, United States of America.
Knudsen N; Ambrx Incorporated, La Jolla, CA, United States of America.
Allen M; Ambrx Incorporated, La Jolla, CA, United States of America.
Buechler Y; Ambrx Incorporated, La Jolla, CA, United States of America.

PLoS One ; 18(7): e0284198, 2023.

Article em En | MEDLINE | ID: mdl-37428761

Assuntos

Antineoplásicos; Imunoconjugados; Anticorpos Monoclonais/química; Oligopeptídeos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoconjugados / Antineoplásicos Tipo de estudo: Guideline Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google